Liang Y et al. |
A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. |
2017 |
Theranostics |
pmid:28900511
|
Khot A et al. |
Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. |
2017 |
AAPS J |
pmid:28808917
|
Menderes G et al. |
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. |
2017 |
Clin. Cancer Res. |
pmid:28679774
|
Kolodych S et al. |
Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. |
2017 |
Eur J Med Chem |
pmid:28818506
|
Du ZQ et al. |
Combination of traditional mutation and metabolic engineering to enhance ansamitocin P-3 production in Actinosynnema pretiosum. |
2017 |
Biotechnol. Bioeng. |
pmid:28782796
|
Kubizek F et al. |
Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges? |
2017 |
Protein Pept. Lett. |
pmid:28741467
|
Menderes G et al. |
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. |
2017 |
Gynecol. Oncol. |
pmid:28705408
|
RÃos-Luci C et al. |
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. |
2017 |
Cancer Res. |
pmid:28687619
|
Harbeck N et al. |
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. |
2017 |
J. Clin. Oncol. |
pmid:28682681
|
He X et al. |
Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. |
2017 |
Nano Lett. |
pmid:28758755
|
Shafaee MN et al. |
Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. |
2017 |
J Oncol Pract |
pmid:28678590
|
Venkatesa P |
NICE recommends routine NHS funding for Kadcyla. |
2017 |
Lancet Oncol. |
pmid:28648556
|
Zhong P et al. |
cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. |
2017 |
Nanotechnology |
pmid:28574851
|
Loibl S and Gianni L |
HER2-positive breast cancer. |
2017 |
Lancet |
pmid:27939064
|
Ohashi K et al. |
Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. |
2017 |
Clin Lung Cancer |
pmid:27497829
|
Tumey LN and Han S |
ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers. |
2017 |
Curr Top Med Chem |
pmid:29357803
|
Meng H et al. |
A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. |
2017 |
Macromol Biosci |
pmid:28464449
|
Singh AP and Shah DK |
Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). |
2017 |
AAPS J |
pmid:28374319
|
Altundag K |
Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer. |
2017 |
J. Neurooncol. |
pmid:28337582
|
Sang H et al. |
Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. |
2017 |
Anal. Chim. Acta |
pmid:28088282
|